Dec 7, 2024, 03:06
Neoadjuvant Chemotherapy plus Immune Checkpoint Inhibitors in Gastroesophageal Cancers
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a recent article by A. Cammarota on X:
“Neoadjuvant chemotherapy plus immune checkpoint inhibitors in gastroesophageal cancers in The European Society for Medical Oncology (ESMO).
- Adding ICI improves response rates.
- PD-L1 is associated with response: 5% or 10% may be cut-off.
Biomarker selected neoadjuvant trials in operable GE cancer.”
Authors: A. Cammarota, S.K. Kamarajah, S. Markar and E.C. Smyth
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
More posts featuring Erman Akkus.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 16:16
Feb 22, 2025, 16:04
Feb 22, 2025, 16:00
Feb 22, 2025, 15:54
Feb 22, 2025, 15:48
Feb 22, 2025, 15:33
Feb 22, 2025, 15:14
Feb 22, 2025, 15:04
Feb 22, 2025, 14:43
Feb 22, 2025, 14:10
Feb 22, 2025, 13:28
Feb 22, 2025, 13:10